Prelude Therapeutics reported a net loss of $31.2M in Q2 2025 and had no revenue for the quarter. R&D and G&A expenses both declined YoY. The company ended the quarter with $77.3M in total cash, cash equivalents, restricted cash, and marketable securities, expected to support operations into Q2 2026.

Prelude Therapeutics reported a net loss of $32.1 million for Q1 2025, consistent with $0.42 EPS, and maintained a cash runway into Q2 2026. The company made significant progress in its SMARCA2 degrader programs, with PRT3789 nearing completion of dose escalation and PRT7732 advancing rapidly in Phase 1. Preclinical data for KAT6A degraders were also presented, with plans to advance these assets.

Prelude Therapeutics reported a net loss of $127.2 million for the full year 2024, with research and development expenses increasing to $118.0 million. The company anticipates its existing cash runway will fund operations into the second quarter of 2026.

Prelude Therapeutics reported its third quarter financial results, highlighting the clinical proof of concept for PRT3789, its IV SMARCA2 degrader, and the initiation of a Phase 1 trial for PRT7732, its oral SMARCA2 degrader. The company's cash runway extends into 2026, with $153.6 million in cash, cash equivalents, and marketable securities as of September 30, 2024.